tirzepatide risk of cancer and in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis Tirzepatide Side Effects Cancer: What

The combination is said to slow the emptying of the stomach by making people feel full longer, suppress appetite by slowing hunger signals to the brain, and help reduce blood sugar

Tesamorelin alone has the strong visceral-fat data

Tirzepatide was associated with larger decreases in glycated hemoglobin and body weight compared to Semaglutide in head-to-head analysis (Del Prato, The Lancet )

It is important to appreciate, however, that the increased risk relates to a disorder that is relatively uncommon. Given the numbers of participants who have been recruited to clinical trials and the large number of people globally who use GLP-1 RAs, we should be confident that if corroborated, the absolute risk of developing NAION in direct relation to taking semaglutide must indeed be rare, Susan Mollan, MBcHP, of University Hospitals Birmingham NHS Foundation Trust , in England, wrote in a commentary published with the study

Medically reviewed by Oghenefejiro Okifo | MD , Harvard Medical School | Henry Ford Hospital - Detroit, MI on December 10th, 2025

While healthy habits are essential, biology and genetics also play an important role, said Donnell Jones, CRNP, UPMC Central PA Medical Weight Management Center